News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,651 Results
Type
Article (41929)
Company Profile (333)
Press Release (665389)
Section
Business (210172)
Career Advice (2081)
Deals (36583)
Drug Delivery (100)
Drug Development (82854)
Employer Resources (171)
FDA (16491)
Job Trends (15361)
News (355500)
Policy (33832)
Tag
Academia (2574)
Alliances (51189)
Alzheimer's disease (1280)
Approvals (16452)
Artificial intelligence (158)
Bankruptcy (362)
Best Places to Work (11717)
Biotechnology (215)
Breast cancer (193)
Cancer (1402)
Cardiovascular disease (116)
Career advice (1742)
Cell therapy (286)
Clinical research (66252)
Collaboration (498)
Compensation (267)
COVID-19 (2613)
C-suite (111)
Data (1406)
Diabetes (179)
Diagnostics (6255)
Earnings (86580)
Employer resources (149)
Events (112884)
Executive appointments (405)
FDA (17190)
Funding (439)
Gene therapy (206)
GLP-1 (633)
Government (4453)
Healthcare (18880)
Infectious disease (2706)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16623)
Job creations (4052)
Job search strategy (1489)
Layoffs (439)
Legal (8329)
Lung cancer (200)
Lymphoma (100)
Manufacturing (216)
Medical device (13300)
Medtech (13305)
Mergers & acquisitions (20122)
Metabolic disorders (479)
Neuroscience (1614)
NextGen Class of 2024 (6626)
Non-profit (4516)
Northern California (1711)
Obesity (272)
Opinion (207)
Patents (124)
People (58429)
Phase I (20521)
Phase II (29150)
Phase III (21860)
Pipeline (517)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (276)
Real estate (6241)
Regulatory (22529)
Research institute (2360)
Resumes & cover letters (358)
Southern California (1479)
Startups (3712)
United States (15446)
Vaccines (583)
Weight loss (197)
Date
Today (2)
Last 7 days (256)
Last 30 days (2163)
Last 365 days (35787)
2024 (35719)
2023 (40630)
2022 (51798)
2021 (56330)
2020 (54794)
2019 (47406)
2018 (35772)
2017 (33139)
2016 (32665)
2015 (38616)
2014 (32517)
2013 (27631)
2012 (29731)
2011 (30492)
2010 (28499)
Location
Africa (776)
Arizona (203)
Asia (40158)
Australia (6424)
California (3863)
Canada (1467)
China (317)
Colorado (176)
Connecticut (181)
Europe (85497)
Florida (540)
Georgia (136)
Illinois (397)
Indiana (233)
Maryland (642)
Massachusetts (3025)
Michigan (177)
Minnesota (293)
New Jersey (1125)
New York (1100)
North Carolina (761)
Northern California (1711)
Ohio (146)
Pennsylvania (936)
South America (1158)
Southern California (1479)
Texas (565)
Utah (109)
Washington State (408)
707,651 Results for "essa pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
ESSA Pharma Inc. today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York.
May 30, 2024
·
1 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2024.
May 14, 2024
·
10 min read
Press Releases
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
December 17, 2024
·
8 min read
Biotech Bay
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ESSA Pharma Inc. today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.
April 9, 2024
·
1 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2023.
February 13, 2024
·
11 min read
Business
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
·
1 min read
Press Releases
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
October 31, 2024
·
8 min read
Biotech Bay
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
ESSA Pharma Inc. today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
February 6, 2024
·
1 min read
Drug Development
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
July 9, 2024
·
1 min read
Business
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.
December 12, 2023
·
11 min read
1 of 70,766
Next
